| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFSF18 |
| Uniprot No | Q9UNG2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 74-199aa |
| 氨基酸序列 | ETAKEPCMAK FGPLPSKWQM ASSEPPCVNK VSDWKLEILQ NGLYLIYGQV APNANYNDVA PFEVRLYKNK DMIQTLTNKS KIQNVGGTYE LHVGDTIDLI FNSEHQVLKN NTYWGIILLA NPQFIS |
| 预测分子量 | 14.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFSF18重组蛋白的3篇参考文献概览：
---
1. **标题**：*Recombinant TNFSF18 enhances antitumor immunity by modulating regulatory T cell function*
**作者**：Wang et al. (2018)
**摘要**：研究通过体外和体内实验证明，重组TNFSF18蛋白可抑制调节性T细胞(Treg)的免疫抑制活性，同时增强效应T细胞的抗肿瘤反应，为癌症免疫治疗提供新策略。
---
2. **标题**：*Structural and functional characterization of TNFSF18/GITRL in autoimmune disease models*
**作者**：Saito et al. (2015)
**摘要**：解析了重组TNFSF18蛋白的晶体结构，并验证其与受体GITR的相互作用，实验表明TNFSF18重组蛋白在类风湿性关节炎模型中加剧炎症反应，提示其病理作用及潜在治疗靶点。
---
3. **标题**：*TNFSF18 recombinant protein promotes T cell activation and survival in chronic infection*
**作者**：Zhang et al. (2020)
**摘要**：研究发现重组TNFSF18通过激活NF-κB信号通路增强CD4+ T细胞的存活与增殖，在慢性病毒感染模型中显著改善T细胞耗竭，为感染性疾病免疫调节提供依据。
---
这些研究涵盖了TNFSF18重组蛋白在肿瘤免疫、自身免疫疾病机制及感染免疫中的多重作用，体现了其在基础研究与临床应用中的广泛潜力。
TNFSF18 (Tumor Necrosis Factor Superfamily Member 18), also known as GITR Ligand (GITRL) or AITRL, is a type II transmembrane protein belonging to the TNF superfamily. It plays a critical role in immune regulation by interacting with its receptor, GITR (Glucocorticoid-Induced TNFR-Related Protein), which is expressed on activated T cells, regulatory T cells (Tregs), and innate immune cells. The TNFSF18-GITR axis modulates T-cell activation, differentiation, and survival, balancing immune responses between tolerance and inflammation. TNFSF18 exists in both membrane-bound and soluble forms, with the latter generated through proteolytic cleavage or alternative splicing.
Recombinant TNFSF18 protein is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) or bacterial systems to ensure proper folding and bioactivity. It retains the functional TNF homology domain, enabling receptor binding and downstream signaling. Studies highlight its dual role: enhancing effector T-cell responses while suppressing Treg-mediated immune suppression, making it a potential therapeutic target in cancer immunotherapy. Conversely, its dysregulation is linked to autoimmune diseases, suggesting context-dependent effects.
In research, recombinant TNFSF18 is used to study immune checkpoint pathways, evaluate GITR-targeting therapies, or develop combination strategies with PD-1/CTLA-4 inhibitors. Preclinical models demonstrate that GITR agonism can promote antitumor immunity by boosting CD8+ T-cell function and destabilizing Tregs. However, clinical trials have shown mixed outcomes, underscoring the need for optimized dosing and biomarker selection. Beyond oncology, TNFSF18 recombinant protein aids in exploring autoimmune mechanisms and tolerance induction. Its versatility in modulating adaptive immunity continues to drive interest in both therapeutic and mechanistic investigations.
×
